Literature DB >> 3788179

[Heart function in infants and small children, whose mothers required tocolysis with hexoprenaline sulfate (Gynipral)].

G Trittenwein, H Rosegger, A Beitzke, W Lichtenegger, K Rosanelli, H L Zeichen.   

Abstract

Cardiac function was investigated in 23 retrospectively selected children (mean age 15 months, range 2/12-3 4/12), whose mothers had undergone a successful course of tocolysis around the 31st week of pregnancy. Hexoprenaline sulfate (Gynipral) had been given at a mean cumulative dose of 51,103 micrograms over an average period of 13.8 days. The infants were born at term; cases with marked birth asphyxia, low birth weight or other perinatal problems possibly influencing cardiac performance were not included. The examination included a chest X-ray, ECG (all standard leads) and ultrasonography. There was no evidence of myocardial dysfunction which might have been the late result of untoward effects of the beta 2-mimetics given during the last trimester of pregnancy. All probands were normally developed: on cardiological examination an incidental systolic murmur was found in 2 infants and border-line cardiomegaly in another proband. ECG revealed a wandering pace-maker and occasional ventricular extrasystoles in one 3 month-old boy, which is not necessarily abnormal at this age. Two-dimensional echocardiography showed normal cardiac anatomy in all 23 probands. One-dimensional M-mode showed normal left ventricular function parameters. The slightly elevated myocardial contractility demonstrated by means of the M-mode was attributed to increased sympathetic tone in the non-sedated children.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3788179

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  1 in total

1.  Assessment of foetal risk associated with 93 non-US-FDA approved medications during pregnancy.

Authors:  Ahmed H Al-Jedai; Sakra S Balhareth; Roaa A Algain
Journal:  Saudi Pharm J       Date:  2012-05-19       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.